CD22: A multifunctional receptor that regulates B lymphocyte survival and signal transduction

Advances in Immunology

Volumn 88, Issue , 2005, Pages 1-50

  Tedder, Thomas F ^a   Poe, Jonathan C ^a   Haas, Karen M ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B LYMPHOCYTE ANTIGEN; CD19 ANTIGEN; CD22 ANTIGEN; CD22 MONOCLONAL ANTIBODY; COMPLEMENT COMPONENT C3D RECEPTOR; IMMUNOGLOBULIN M; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY; PROTEIN TYROSINE KINASE; UNCLASSIFIED DRUG;

ANTIGEN EXPRESSION; AUTOIMMUNE DISEASE; B CELL LYMPHOMA; B LYMPHOCYTE ACTIVATION; CELL ACTIVATION; CELL PROLIFERATION; CELL SURFACE; CELL SURVIVAL; CLINICAL TRIAL; CYTOPLASM; ENZYME ACTIVATION; GENE AMPLIFICATION; GENE CONTROL; HOMEOSTASIS; HUMAN; LIGAND BINDING; LYMPHOCYTE; MOLECULAR DYNAMICS; NONHUMAN; PRIORITY JOURNAL; PROTEIN STRUCTURE; RECEPTOR BINDING; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; ANTIGENS, CD22; ANTIGENS, CD40; AUTOIMMUNITY; B-LYMPHOCYTES; CELL SURVIVAL; FEEDBACK, PHYSIOLOGICAL; GENE EXPRESSION REGULATION; HUMANS; IMMUNE SYSTEM; IMMUNE TOLERANCE; IMMUNITY, HUMORAL; IMMUNOTHERAPY; MICE; NEOPLASMS; PROTEIN BINDING; RECEPTORS, ANTIGEN, B-CELL; SIGNAL TRANSDUCTION; SRC-FAMILY KINASES;

EID: 26644450721     PISSN: 00652776     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0065-2776(05)88001-0     Document Type: Review

References (223)

1. Amlot P.L., Stone M.J., Cunningham D., Fay J., Newman J., Collins R., May R., McCarthy M., Richardson J., and Ghetie V. A phase I study of anti-CD22-deglycosylated ricin A chain immunotoxin in the treatment of B-cell lymphomas resistant to conventional therapy Blood 82 1993 2624 2633
2. Aruffo A., Kanner S.B., Sgroi D., Ledbetter J.A., and Stamenkovic I. CD22-mediated stimulation of T cells regulates T-cell receptor/CD3-induced signaling Proc. Natl. Acad. Sci. USA 89 1992 10242 10246
3. Bast B.J., Zhou L.-J., Freedman G.J., Colley K.J., Ernst T.J., Munro J.M., and Tedder T.F. The HB-6, CDw75, and CD76 differentiation antigens are unique cell-surface carbohydrate determinants generated by the β-galactoside α2,6-sialyltransferase J. Cell Biol. 116 1992 423 435
4. Batten M., Groom J., Cachero T.G., Qian F., Schneider P., Tschopp J., Browning J.L., and Mackay F. BAFF mediates survival of peripheral immature B lymphocytes J. Exp. Med. 192 2000 1453 1466
5. Bell S.E., and Goodnow C.C. A selective defect in IgM antigen receptor synthesis and transport causes loss of cell surface IgM expression on tolerant B lymphocytes EMBO J. 13 1994 816 826
6. Blasioli J., Paust S., and Thomas M.L. Definition of the sites of interaction between the protein tyrosine phosphatase SHP-1 and CD22 J. Biol. Chem. 274 1999 2303 2307
7. Boackle S.A., Holers V.M., Chen X., Szakonyi G., Karp D.R., Wakeland E.K., and Morel L. Cr2, a candidate gene in the murine Sle1c lupus susceptibility locus, encodes a dysfunctional protein Immunity 15 2001 775 785
8. Bolland S., Pearse R.N., Kurosaki T., and Ravetch J.V. SHIP modulates immune receptor responses by regulating membrane association of Btk Immunity 8 1998 509 516
9. Bolognesi A., Tazzari P.L., Oliveri F., Polito L., Lemoli R., Rerenzi A., Pasqualucci L., Falini B., and Stirpe F. Evaluation of immunotoxins containing single-chain ribosome-inactivating proteins and an anti-CD22 monoclonal antibody (OM124): In vitro and in vivo studies Brit. J. Hematol. 101 1998 179 188
10. Bonardi M.A., Bell A., French R.R., Gromo G., Hamblin T., Modena D., Tutt A.L., and Glennie M.J. Initial experience in treating human lymphoma with a combination of bispecific antibody and saporin Intl. J. Cancer - Supplement 7 1992 73 77
11. Bonardi M.A., French R.R., Amlot P., Gromo G., Modena D., and Glennie M.J. Delivery of saporin to human B-cell lymphoma using bispecific antibody: Targeting via CD22 but not CD19, CD37, or immunoglobulin results in efficient killing Cancer Res. 53 1993 3015 3021
12. Boue D.R., and LeBien T.W. Expression and structure of CD22 in acute leukemia Blood 71 1988 1480 1486
13. Boue D.R., and LeBien T.W. Structural characterization of the human B lymphocyte-restricted differentiation antigen CD22. Comparison with CD21 (complement receptor type 2/Epstein Barr virus receptor) J. Immunol. 140 1988 192 199
14. Buhl A.M., and Cambier J.C. Co-receptor and accessory regulation of B-cell antigen receptor signal transduction Immunol. Rev. 160 1997 127 138
15. Buhl A.M., and Cambier J.C. Phosphorylation of CD19 Y484 and Y515, and linked activation of phosphatidylinositol 3-kinase, are required for B-cell antigen receptor-mediated activation of Bruton's tyrosine kinase J. Immunol. 162 1999 4438 4446
16. 2+ mobilization J. Exp. Med. 186 1997 1897 1910
17. Bustelo X.R., and Barbacid M. Tyrosine phosphorylation of the Vav proto-oncogene product in activated B cells Science 256 1992 1196 1199
18. Campbell M.A., and Klinman N.R. Phosphotyrosine-dependent association between CD22 and protein tyrosine phosphatase 1C Eur. J. Immunol. 25 1995 1573 1579
19. Carnahan J., Wang P., Kendall R., Chen C., Hu S., Boone T., Juan T., Talvenheimo J., Montestruque S., Sun J., Elliott G., Thomas J., Ferbas J., Kern B., Briddell R., Leonard J.P., and Cesano A. Epratuzumab, a humanized monoclonal antibody targeting CD22: Characterization of in vitro properties Clin. Cancer Res. 9 2003 3982S 3990S
20. Castigli E., Alt F.W., Davidson L., Bottaro A., Mizoguchi E., Bhan A.K., and Geha R.S. CD40-deficient mice generated by recombination-activating gene-2-deficient blastocyst complementation Proc. Natl. Acad. Sci. USA 91 1994 12135 12139
21. Chacko G.W., Tridandapani S., Damen J.E., Liu L., Krystal G., and Coggeshall K.M. Negative signaling in B lymphocytes induces tyrosine phosphorylation of the 145-kDa inositol polyphosphate 5-phosphatase, SHIP J. Immunol. 157 1996 2234 2238
22. Chan O.T., Hannum L.G., Haberman A.M., Madaio M.P., and Shlomchik M.J. A novel mouse with B cells but lacking serum antibody reveals an antibody-independent role for B cells in murine lupus J. Exp. Med. 189 1999 1639 1648
23. Chan O.T., Madaio M.P., and Shlomchik M.J. The central and multiple roles of B cells in lupus pathogenesis Immunol. Rev. 169 1999 107 121
24. Chan V.W.F., Lowell C.A., and DeFranco A.L. Defective negative regulation of antigen receptor signaling in Lyn-deficient B lymphocytes Curr. Biol. 8 1998 545 553
25. Chaouchi N., Vazquez A., Galanaud P., and Leprince C. B-cell antigen receptor-mediated apoptosis. Importance of accessory molecules CD19 and CD22, and of surface IgM cross-linking J. Immunol. 154 1995 3096 3104
26. Chen J., McLean P.A., Neel B.G., Okunade G., Shull G.E., and Wortis H.H. CD22 attenuates calcium signaling by potentiating plasma membrane calcium-ATPase activity Nat. Immunol. 5 2004 651 657
27. Chen X., Martin F., Forbush K.A., Perlmutter R.M., and Kearney J.F. Evidence for selection of a population of multi-reactive B cells into the splenic marginal zone Int. Immunol. 9 1997 27 41
28. Clynes R.A., Towers T.L., Presta L.G., and Ravetch J.V. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets Nat. Med. 6 2000 443 446
29. Coleman M., Goldenberg D.M., Siegel A.B., Ketas J.C., Ashe M., Fiore J.M., and Leonard J.P. Epratuzumab: Targeting B-cell malignancies through CD22 Clin. Cancer Res. 9 2003 3991S 3994S
30. Collins B.E., Blixt O., Bovin N.V., Danzer C.-P., Chui D., Marth J.D., Nitschke L., and Paulson J.C. Constitutively unmasked CD22 on B cells of ST6Gal I knockout mice: Novel sialoside probe for murine CD22 Glycobiology 12 2002 563 571
31. Collins B.E., Blixt O., De Sieno A.R., Bovin N., Marth J.D., and Paulson J.C. Masking of CD22 by cis ligands does not prevent redistribution of CD22 to sites of cell contact Proc. Natl. Acad. Sci. USA 101 2004 6104 6109
32. Collins T.L., Deckert M., and Altman A. Views on Vav Immunol. Today 18 1997 221 225
33. Crespo P., Schuebel K.E., Ostrom A.A., Gutkind J.S., and Bustelo X.R. Phosphotyrosine-dependent activation of Rac-1 GDP/GTP exchange by the Vav proto-oncogene product Nature 385 1997 169 172
34. Crocker P.R., Mucklow S., Bouckson V., McWilliam A., Willis A.C., Gordon S., Milon G., Kelm S., and Bradfield P. Sialoadhesin, a macrophage sialic acid-binding receptor for haemopoietic cells with 17 immunoglobulin-like domains EMBO J. 13 1994 4490 4503
35. Crowley M.T., Harmer S.L., and DeFranco A.L. Activation-induced association of a 145-kDa tyrosine-phosphorylated protein with Shc and Syk in B lymphocytes and macrophages J. Biol. Chem. 271 1996 1145 1152
36. Cyster J.G., and Goodnow C.C. Protein tyrosine phosphatase 1C negatively regulates antigen receptor signaling in B lymphocytes and determines thresholds for negative selection Immunity 2 1995 13 24
37. Cyster J.G., and Goodnow C.C. Tuning antigen receptor signaling by CD22: Integrating cues from antigens and the microenvironment Immunity 6 1997 509 517
38. Davis J.C. Jr., Totoritis M.C., Rosenberg J., Sklenar T.A., and Wofsy D. Phase I clinical trial of a monoclonal antibody against CD40-ligand (IDEC-131) in patients with systemic lupus erythematosus J. Rheumatol. 28 2001 95 101
39. Dealy M.J., Nguyen K.V., Lo J., Gstaiger M., Krek W., Elson D., Arbeit J., Kipreos E.T., and Johnson R.S. Loss of Cul1 results in early embryonic lethality and dysregulation of cyclin E Nat. Genet. 23 1999 245 248
40. Decker T., Oelsner M., Kreitman R.J., Salvatore G., Wang Q.C., Pastan I., Peschel C., and Licht T. Induction of caspase-dependent programmed cell death in B-cell chronic lymphocytic leukemia by anti-CD22 immunotoxins Blood 103 2004 2718 2726
41. Deckert M., Tertare-Deckert S., Couture C., Mustelin T., and Altman A. Functional and physical interactions of Syk family kinases with the Vav proto-oncogene product Immunity 5 1996 591 604
42. DeFranco A.L., Chan V.W.F., and Lowell C.A. Positive and negative roles of the tyrosine kinase Lyn in B-cell function Semin. Immunol. 10 1998 299 308
43. DiJoseph J.F., Armellino D.C., Boghaert E.R., Khandke K., Dougher M.M., Sridharan L., Kunz A., Hamann P.R., Gorovits B., Udata C., Moran J.K., Popplewell A.G., Stephens S., Frost P., and Damle N.K. Antibody-targeted chemotherapy with CMC-544: A CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies Blood 103 2004 1807 1814
44. DiJoseph J.F., Popplewell A., Tickle S., Ladyman H., Lawson A., Kunz A., Khandke K., Armellino D.C., Boghaert E.R., Hamann P., Zinkewich-Peotti K., Stephens S., Weir N., and Damle N.K. Antibody-targeted chemotherapy of B-cell lymphoma using calicheamicin conjugated to murine or humanized antibody against CD22 Cancer Immunol. Immunother. 54 2005 11 24
45. Doody G.M., Justement L.B., Delibrias C.C., Mathews R.J., Lin J., Thomas M.L., and Fearon D.T. A role in B-cell activation for CD22 and the protein tyrosine phosphatase SHP Science 269 1995 242 244
46. Dörken B., Moldenhauer G., Pezzutto A., Schwartz R., Feller A., Kiesel S., and Nadler L.M. HD39 (B3), a B lineage-restricted antigen whose cell surface expression is limited to resting and activated human B lymphocytes J. Immunol. 136 1986 4470 4479
47. Edwards J.C.W., and Cambridge G. Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes Rheumatology 40 2001 1 7
48. Engel P., Nojima Y., Rothstein D., Zhou L.-J., Wilson G.L., Kehrl J.H., and Tedder T.F. The same epitope on CD22 of B lymphocytes mediates the adhesion of erythrocytes, T and B lymphocytes, neutrophils and monocytes J. Immunol. 150 1993 4719 4732
49. Engel P., Wagner N., Miller A., and Tedder T.F. Identification of the ligand binding domains of CD22, a member of the immunoglobulin superfamily that uniquely binds a sialic acid-dependent ligand J. Exp. Med. 181 1995 1581 1586
50. Engel P., Zhou L.-J., Ord D.C., Sato S., Koller B., and Tedder T.F. Abnormal B lymphocyte development, activation and differentiation in mice that lack or overexpress the CD19 signal transduction molecule Immunity 3 1995 39 50
51. Erickson L.D., Tygrett L.T., Bhatia S.K., Grabstein K.H., and Waldschmidt T.J. Differential expression of CD22 (Lyb8) on murine B cells Int. Immunol. 8 1996 1121 1129
52. Floyd H., Nitschke L., and Crocker P.R. A novel subset of murine B cells that expreses unmasked forms of CD22 is enriched in the bone marrow: Implications for B-cell homing to the bone marrow Immunology 101 2000 342 347
53. French R.R., Bell A.J., Hamblin T.J., Tutt A.L., and Glennie M.J. Response of B-cell lymphoma to a combination of bispecific antibodies and saporin Leuk. Res. 20 1996 607 617
54. French R.R., Hamblin T.J., Bell A.J., Tutt A.L., and Glennie M.J. Treatment of B-cell lymphomas with combination of bispecific antibodies and saporin Lancet 346 1995 223 224
55. French R.R., Penney C.A., Browning A.C., Stirpe F., George A.J., and Glennie M.J. Delivery of the ribosome-inactivating protein, gelonin, to lymphoma cells via CD22 and CD38 using bispecific antibodies Brit. J. Cancer 71 1995 986 994
56. Fujimoto M., Bradney A.P., Poe J.C., Steeber D.A., and Tedder T.F. Modulation of B lymphocyte antigen receptor signal transduction by a CD19/CD22 regulatory loop Immunity 11 1999 191 200
57. Fujimoto M., Fujimoto Y., Poe J.C., Jansen P.J., Lowell C.A., DeFranco A.L., and Tedder T.F. CD19 regulates Src-family protein tyrosine kinase activation in B lymphocytes through processive amplification Immunity 13 2000 47 57
58. 2+ responses: A role for Lyn sequestration in extinguishing negative regulation J. Biol. Chem. 276 2001 44820 44827
59. Fujimoto M., Poe J.C., Inaoki M., and Tedder T.F. CD19 regulates B lymphocyte responses to transmembrane signals Semin. Immunol. 10 1998 267 277
60. Fujimoto M., Poe J.C., Jansen P.J., Sato S., and Tedder T.F. CD19 amplifies B lymphocyte signal transduction by regulating Src-family protein tyrosine kinase activation J. Immunol. 162 1999 7088 7094
61. Ghetie M.-A., May R.D., Till M., Uhr J.W., Ghetie V., Knowles P.P., Relf M., Brown A., Wallace P.M., Janossy G., Amlot P., and Vitetta E.S. Evaluation of ricin A chain-containing immunotoxins directed against CD19 and CD22 antigens on normal and malignant human B-cells as potential reagents for in vivo therapy Cancer Res. 48 1988 2610 2617
62. Ghetie M.-A., Picker L.J., Richardson J.A., Tucker K., Uhr J.W., and Vitetta E.S. Anti-CD19 inhibits the growth of human B-cell tumor lines in vitro and of Daudi cells in SCID mice by inducing cell cycle arrest Blood 83 1994 1329 1336
63. Ghetie M.-A., Tucker K., Richardson J., Uhr J.W., and Vitetta E.S. The antitumor activity of an anti-CD22 immunotoxin in SCID mice with disseminated Daudi lymphoma is enhanced by either an anti-CD19 antibody or an anti-CD19 immunotoxin Blood 80 1992 2315 2320
64. Goodnow C.C., Crosbie J., Adelstein S., Lavoie T.B., Smith-Gill S.J., Brink R.A., Pritchard-Briscoe H., Wotherspoon J.S., Loblay R.H., Raphael K., Trent R.J., and Basten A. Altered immunoglobulin expression and functional silencing of self-reactive B lymphocytes in transgenic mice Nature 334 1988 676 682
65. Gordon J. CD40 and its ligand: Central players in B lymphocyte survival, growth, and differentiation Blood Rev. 9 1995 53 56
66. Grimaldi C.M., Cleary J., Dagtas A.S., Moussai D., and Diamond B. Estrogen alters thresholds for B-cell apoptosis and activation J. Clin. Invest. 109 2002 1625 1633
67. Grimaldi C.M., Michael D.J., and Diamond B. Cutting Edge: Expansion and activation of a population of autoreactive marginal zone B cells in a model of estrogen-induced lupus J. Immunol. 167 2001 1886 1890
68. Groom J., Kalled S.L., Cutler A.H., Olson C., Woodcock S.A., Schneider P., Tschopp J., Cachero T.G., Batten M., Wheway J., Mauri D., Cavill D., Gordon T.P., Mackay C.R., and Mackay F. Association of BAFF/BLyS overexpression and altered B-cell differentiation with Sjögren's syndrome J. Clin. Invest. 109 2002 59 68
69. Gross J.A., Dillon S.R., Mudri S., Johnston J., Littau A., Roque R., Rixon M., Schou O., Foley K.P., Haugen H., McMillen S., Waggie K., Schreckhise R.W., Shoemaker K., Vu T., Moore M., Grossman A., and Clegg C.H. TACI-Ig neutralizes molecules critical for B-cell development and autoimmune disease. Impaired B-cell maturation in mice lacking BLyS Immunity 15 2001 289 302
70. Gross J.A., Johnston J., Mudri S., Enselman R., Dillon S.R., Madden K., Xu W., Parrish-Novak J., Foster D., Lofton-Day C., Moore M., Littau A., Grossman A., Haugen H., Foley K., Blumberg H., Harrison K., Kindsvogel W., and Clegg C.H. TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease Nature 404 2000 995 999
71. Guinamard R., Okigaki M., Schlessinger J., and Ravetch J.V. Absence of marginal zone B cells in Pyk-2-deficient mice defines their role in the humoral responses Nat. Immunol. 1 2000 31 36
72. Haas K.M., Hasegawa M., Steeber D.A., Poe J.C., Zabel M.D., Bock C.B., Karp D.R., Briles D.E., Weis J.H., and Tedder T.F. Complement receptors CD21/35 link innate and protective immunity during Streptococcus pneumoniae infection by regulating IgG3 antibody responses Immunity 17 2002 713 723
73. Hamaguchi Y., Uchida J., Cain D.W., Venturi G.M., Poe J.C., Haas K.M., and Tedder T.F. The peritoneal cavity provides a protective niche for B1 and conventional B lymphocytes during anti-CD20 immunotherapy in mice J. Immunol. 7 2005 4389 4399
74. Hanasaki K., Powell L.D., and Varki A. Binding of human plasma sialoglycoproteins by the B-cell-specific lectin CD22: Selective recognition of immunoglobulin M and haptoglobin J. Biol. Chem. 270 1995 7543 7550
75. Harmer S.L., and DeFranco A.L. The Src homology domain 2-containing inositol phosphatase SHIP forms a ternary complex with Shc and Grb2 in antigen receptor-stimulated B lymphocytes J. Biol. Chem. 274 1998 12183 12191
76. Hasegawa M., Fujimoto M., Poe J.C., Steeber D.A., and Tedder T.F. CD19 can regulate B lymphocyte signal transduction independent of complement activation J. Immunol. 167 2001 3190 3200
77. Hennet T., Chui D., Paulson J.C., and Marth J.D. Immune regulation by the ST6Gal sialyltransferase Proc. Natl. Acad. Sci. USA 95 1998 4504 4509
78. Hibbs M.L., Tarlinton D.M., Armes J., Grail D., Hodgson G., Maglitto R., Stacker S.A., and Dunn A.R. Multiple defects in the immune system of Lyn-deficient mice, culminating in autoimmune disease Cell 83 1995 301 311
79. 2+ mobilization is integrated by CD19 dephosphorylation Immunity 7 1997 49 58
80. Huang W., Sinha J., Newman J., Reddy B., Budhai L., Furie R., Vaishnaw A., and Davidson A. The effect of anti-CD40 ligand antibody on B cells in human systemic lupus erythematosus Arthritis Rheum. 46 2002 1554 1562
81. Inaoki M., Sato S., Weintraub B.C., Goodnow C.C., and Tedder T.F. CD19-regulated signaling thresholds control peripheral tolerance and autoantibody production in B lymphocytes J. Exp. Med. 186 1997 1923 1931
82. Jin L., McLean P.A., Neel B.G., and Wortis H.H. Sialic acid binding domains of CD22 are required for negative regulation of B-cell receptor signaling J. Exp. Med. 195 2002 1199 1205
83. Juweid M.E., Stadtmauer E., Hajjar G., Sharkey R.M., Suleiman S., Luger S., Swayne L.C., Alavi A., and Goldenberg D.M. Pharmacokinetics, dosimetry, and initial therapeutic results with 131I- and (111)In-/90Y-labeled humanized LL2 anti-CD22 monoclonal antibody in patients with relapsed, refractory non-Hodgkin's lymphoma Clin. Cancer Res. 5 1999 3292 3302
84. Kavanaugh W.M., Pot D.A., Chin S.M., Deuter-Reinhard M., Jefferson A.B., Norris F.A., Masiarz F.R., Cousens L.S., Majerus P.W., and Williams L.T. Multiple forms of an inositol polyphosphate 5-phosphatase form signaling complexes with Shc and Grb2 Curr. Biol. 6 1996 438 445
85. Kawabe T., Naka T., Yoshida K., Tanaka T., Fujiwara H., Suematsu N., Yoshida N., Kishimoto T., and Kikutani H. The immune responses in the CD40-deficient mice: Impaired immunoglobulin class switching and germinal center formation Immunity 1 1994 167 178
86. Kelm S., Gerlach J., Brossmer R., Danzer C.-P., and Nitschke L. The ligand-binding domain of CD22 is needed for inhibition of the B-cell receptor signal, as demonstrated by a novel human CD22-specific inhibitor compound J. Exp. Med. 195 2002 1207 1213
87. Kelm S., Pelz A., Schauer R., Filbin M.T., Tang S., de Bellard M.-E., Schnaar R.L., Mahoney J.A., Hartnell A., Bradfield P., and Crocker P.R. Sialoadhesin, myelin-associated glycoprotein and CD22 define a new family of sialic acid-dependent adhesion molecules of the immunoglobulin superfamily Curr. Biol. 4 1994 965 972
88. Kono D.H., Burlingame R.W., Owens D.G., Kuramochi A., Balderas R.S., Balomenos D., and Theofilopoulos A.N. Lupus susceptibility loci in New Zealand mice Proc. Natl. Acad. Sci. USA 91 1994 10168 10172
89. Kozlowski M., Mlinaric-Rascan I., Feng G.S., Shen R., Pawson T., and Siminovitch K.A. Expression and catalytic activity of the tyrosine phosphatase PTP1C is severely impaired in motheaten and viable motheaten mice J. Exp. Med. 178 1993 2157 2163
90. Kreitman R.J., Wang Q.C., Fitz Gerald D.J., and Pastan I. Complete regression of human B-cell lymphoma xenografts in mice treated with recombinant anti-CD22 immunotoxin RFB4(dsFv)-PE38 at doses tolerated by cynomolgus monkeys Intl. J. Cancer 81 1999 148 155
91. Kreitman R.J., Wilson W.H., Bergeron K., Raggio M., Stetler-Stevenson M., Fitz Gerald D.J., and Pastan I. Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia N. Engl. J. Med. 345 2001 241 247
92. Kremer J.M., Westhovens R., Leon M., Di Giorgio E., Alten R., Steinfeld S., Russell A., Dougados M., Emery P., Nuamah I.F., Williams G.R., Becker J.C., Hagerty D.T., and Moreland L.W. Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig N. Engl. J. Med. 349 2003 1907 1915
93. Lajaunias F., Ibnou-Zekri N., Jimack L.F., Chichepertiche Y., Parkhouse R.M.E., Reininger C.M.L., Brighouse G., and Izui S. Polymorphisms in the Cd22 gene of inbred mouse strains Immunogenetics 49 1999 991 995
94. Lankester A.C., van Schijndel G.M., and van Lier R.A. Hematopoietic cell phosphatase is recruited to CD22 following B-cell antigen receptor ligation J. Biol. Chem. 270 1995 20305 20308
95. Lanoue A., Batista F.D., Stewart M., and Neuberger M.S. Interaction of CD22 with α2,6-linked sialoglycoconjugates: Innate recognition of self to dampen B-cell autoreactivity? Eur. J. Immunol. 32 2002 348 355
96. Law C.-L., Aruffo A., Chandran K.A., Doty R.T., and Clark E.A. Ig domains 1 and 2 of murine CD22 constitute the ligand-binding domain and bind multiple sialylated ligands expressed on B and T cells J. Immunol. 155 1995 3368 3376
97. γ1 upon B-cell activation J. Exp. Med. 183 1996 547 560
98. Law C.-L., Torres R.M., Sundberg H.A., Parkhouse R.M.E., Brannan C.I., Copeland N.G., Jenkins N.A., and Clark E.A. Organization of the murine Cd22 locus. Mapping to chromosome 7 and characterization of two alleles J. Immunol. 151 1993 17 87
99. Leandro M.J., Edwards J.C., and Cambridge G. Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion Ann. Rheum. Dis. 61 2002 883 888
100. Leandro M.J., Edwards J.C., Cambridge G., Ehrenstein M.R., and Isenberg D.A. An open study of B lymphocyte depletion in systemic lupus erythematosis Arthritis Rheum. 46 2002 2673 2677
101. Leonard J.P., and Link B.K. Immunotherapy of non-Hodgkin's lymphoma with hLL2 (epratuzumab, an anti-CD22 monoclonal antibody) and Hu1D10 (apolizumab) Semin. Oncol. 29 2002 81 86
102. Leprince C., Draves K.E., Geahlen R.L., Ledbetter J.A., and Clark E.A. CD22 associates with the human surface IgM-B-cell antigen receptor complex Proc. Natl. Acad. Sci. USA 90 1993 3236 3240
103. Li T.J., Rawlings D.J., Park H., Kato R.M., Witte O.N., and Satterthwaite A.B. Constitutive membrane association potentiates activation of Bruton's tyrosine kinase Oncogene 15 1997 1375 1383
104. Li Z.M., Wahl M.I., Eguinoa A., Stephens L.R., Hawkins P.T., and Witte O.N. Phosphatidylinositol 3-kinase-γ activates Bruton's tyrosine kinase in concert with Src family kinases Proc. Natl. Acad. Sci. USA 94 1997 13820 13825
105. Liu Q., Oliveira-Dos Santos A.J., Mariathasan S., Bouchard D., Jones J., Sarao R., Kozieradzki I., Ohashi P.S., Pennigner J.M., and Dumont D.J. The inositol polyphosphate 5-phosphatase Ship is a crucial negative regulator of B-cell antigen receptor signaling J. Exp. Med. 188 1998 1333 1342
106. Mackay F., Sierro F., Grey S.T., and Gordon T.P. The BAFF/APRIL system: An important player in systemic rheumatic diseases Curr. Dir. Autoimmunity 8 2005 243 265
107. Mackay F., Woodcock S.A., Lawton P., Ambrose C., Baetscher M., Schneider P., Tschopp J., and Browning J.L. Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations J. Exp. Med. 190 1999 1697 1710
108. Madaio M.P. B cells and autoantibodies in the pathogenesis of lupus nephritis Immunol. Res. 17 1998 123 132
109. Mansfield E., Amlot P., Pastan I., and Fitz Gerald D.J. Recombinant RFB4 immunotoxins exhibit potent cytotoxic activity for CD22-bearing cells and tumors Blood 90 1997 2020 2026
110. Mansfield E., Chiron M.F., Amlot P., Pastan I., and Fitz Gerald D.J. Recombinant RFB4 single-chain immunotoxin that is cytotoxic towards CD22-positive cells Biochem. Soc. Trans. 25 1997 709 714
111. Martin F., and Kearney J.F. B-cell subsets and the mature preimmune repertoire. Marginal zone and B1 B cells as part of a "natural immune memory" Immunol. Rev. 175 2000 70 79
112. Martin F., and Kearney J.F. Marginal-zone B cells Nat. Rev. Immunol. 2 2002 323 335
113. Martin F., Oliver A.M., and Kearney J.F. Marginal zone and B1 B cells unite in the early response against T-independent blood-borne particulate antigens Immunity 14 2001 617 629
114. a lupus-prone mice J. Immunol. 165 2000 2987 2996
115. Morel L., Rudofsky U.H., Longmate J.A., Schiffenbauer J., and Wakeland E.K. Polygenic control of susceptibility to murine systemic lupus erythematosus Immunity 1 1994 219 229
116. Munro S., Bast B.J.E.G., Colley K.J., and Tedder T.F. B lymphocyte surface antigen CD75 is not α-2,6-sialyltransferase but is a carbohydrate antigen modified by the enzyme Cell 68 1992 1003 1004
117. Nadler M.J.S., McLean P.A., Neel B.G., and Wortis H.H. B-cell antigen receptor-evoked calcium influx is enhanced in CD22-deficient B-cell lines J. Immunol. 159 1997 4233 4243
118. Nishizumi H., Taniuchi I., Yamanashi Y., Kitamura D., Ilic D., Mori S., Watanabe T., and Yamamoto T. Impaired proliferation of peripheral B cells and indication of autoimmune disease in lyn-deficient mice Immunity 3 1995 549 560
119. Nitschke L., Carsetti R., Ocker B., Kohler G., and Lamers M.C. CD22 is a negative regulator of B-cell receptor signaling Curr. Biol. 7 1997 133 143
120. Nitschke L., Floyd H., Ferguson D.J.P., and Crocker P.R. Identification of CD22 ligands on bone marrow sinusoidal endothelium implicated in CD22-dependent homing of recirculating B cells J. Exp. Med. 189 1999 1513 1518
121. Nitschke L., and Tsubata T. Molecular interactions regulate BCR signal inhibition by CD22 and CD72 Trends Immunol. 25 2004 543 550
122. O'Hagan R.C., Ohh M., David G., de Alboran I.M., Alt F.W., Kaelin J., W.G., and De Pinho R.A. Myc-enhanced expression of Cul1 promotes ubiquitin-dependent proteolysis and cell cycle progression Genes & Dev. 14 2000 2185 2191
123. O'Keefe T.L., Williams G.T., Batista F.D., and Neuberger M.S. Deficiency in CD22, a B-cell-specific inhibitory receptor, is sufficient to predispose to development of high affinity autoantibodies J. Exp. Med. 189 1999 1307 1313
124. O'Keefe T.L., Williams G.T., Davies S.L., and Neuberger M.S. Hyperresponsive B cells in CD22-deficient mice Science 274 1996 798 801
125. O'Rourke L., Tooze R., and Fearon D.T. Co-receptors of B lymphocytes Curr. Opin. Immunol. 9 1997 324 329
126. 2+ oscillatory response J. Immunol. 161 1998 5129 5132
127. Okano Y. Antinuclear antibody in systemic sclerosis (scleroderma) Rheum. Dis. Clin. North Am. 22 1996 709 735
128. Otipoby K.L., Andersson K.B., Draves K.E., Klaus S.J., Farr A.G., Kerner J.D., Perlmutter R.M., Law C.-L., and Clark E.A. CD22 regulates thymus-independent responses and the lifespan of B cells Nature 384 1996 634 637
129. Pani G., Kozlowski M., Cambier J.C., Mills G.B., and Siminovitch K.A. Identification of the tyrosine phosphatase PTP1C as a B-cell antigen receptor-associated protein involved in the regulation of B-cell signaling J. Exp. Med. 181 1995 2077 2084
130. Peaker C.J.G., and Neuberger M.S. Association of CD22 with the B-cell antigen receptor Eur. J. Immunol. 23 1993 1358 1363
131. Pezzutto A., Dörken B., Moldenhauer G., and Clark E.A. Amplification of human B-cell activation by a monoclonal antibody to the B-cell-specific antigen CD22, Bp130/140 J. Immunol. 138 1987 98 103
132. Pezzutto A., Rabinovitch P.S., Dörken B., Moldenhauer G., and Clark E.A. Role of the CD22 human B-cell antigen in B-cell triggering by anti-immunoglobulin J. Immunol. 140 1988 1791 1795
133. Pflugh D.L., Maher S.E., and Bothwell A.L.M. Ly-6 superfamily members Ly-6A/E, Ly-6C, and Ly-6I recognize two potential ligands expressed by B lymphocytes J. Immunol. 169 2002 5130 5136
134. Poe J.C., Fujimoto M., Jansen P.J., Miller A.S., and Tedder T.F. CD22 forms a quaternary complex with SHIP, Grb2 and Shc. A pathway for regulation of B lymphocyte antigen receptor-induced calcium flux J. Biol. Chem. 275 2000 17420 17427
135. Poe J.C., Fujimoto Y., Hasegawa M., Haas K.M., Miller A.S., Sanford I.G., Bock C.B., Fujimoto M., and Tedder T.F. CD22 regulates B lymphocyte function in vivo through both ligand-dependent and ligand-independent mechanisms Nat. Immunol. 5 2004 1078 1087
136. Poe J.C., Haas K.M., Uchida J., Lee Y., Fujimoto M., and Tedder T.F. Severely-impaired B lymphocyte proliferation, survival and induction of the c-Myc:Cullin 1 ubiquitin ligase pathway resulting from CD22 deficiency on the C57BL/6 genetic background J. Immunol. 172 2004 2100 2110
137. Poe J.C., Hasegawa M., and Tedder T.F. CD19, CD21 and CD22: Multifaceted response regulators of B lymphocyte signal transduction Int. Rev. Immunol. 20 2001 739 762
138. Powell L.D., Sgroi D., Sjoberg E.R., Stamenkovic I., and Varki A. Natural ligands of the B-cell adhesion molecule CD22β carry N-linked oligosaccharides with α-2,6-linked sialic acids that are required for recognition J. Biol. Chem. 268 1993 7019 7027
139. Powell L.D., and Varki A. The oligosaccharide binding specificities of CD22-β, a sialic acid-specific lectin of B-cells J. Biol. Chem. 269 1994 10628 10636
140. Press O.W., Farr A.G., Borroz K.I., Anderson S.K., and Martin P.J. Endocytosis and degradation of monoclonal antibodies targeting human B-cell malignancies Cancer Res. 49 1989 4906 4912
141. Press O.W., Howell-Clark J., Anderson S., and Bernstein I. Retention of B-cell-specific monoclonal antibodies by human lymphoma cells Blood 83 1994 1390 1397
142. Press O.W., Leonard J.P., Coiffier B., Levy R., and Timmerman J. Immunotherapy of Non-Hodgkin's lymphomas Hematology 2001 221 240 (Am. Soc. Hematol. Educ. Program)
143. Prodeus A.P., Goerg S., Shen L.M., Pozdnyakova O.O., Chu L., Alicot E.M., Goodnow C.C., and Carroll M.C. A critical role for complement in maintenance of self-tolerance Immunity 9 1998 721 731
144. Protheroe A., Edwards J.C., Simmons A., Maclennan K., and Selby P. Remission of inflammatory arthropathy in association with anti-CD20 therapy for non-Hodgkin's lymphoma Rheumatology 38 1999 1150 1152
145. Razi N., and Varki A. Masking and unmasking of the sialic acid-binding lectin activity of CD22 (Siglec-2) on B lymphocytes Proc. Natl. Acad. Sci. USA 95 1998 7469 7474
146. Rickert R.C., Rajewsky K., and Roes J. Impairment of T-cell-dependent B-cell responses and B-1 cell development in CD19-deficient mice Nature 376 1995 352 355
147. Saito E., Fujimoto M., Hasegawa M., Komura K., Hamaguchi Y., Kaburagi Y., Nagaoka T., Takehara K., Tedder T.F., and Sato S. CD19-dependent B lymphocyte signaling thresholds influence skin fibrosis and autoimmunity in the tight-skin mouse J. Clin. Invest 109 2002 1453 1462
148. Saleh M.N., Gutheil J., Moore M., Bunch P.W., Butler J., Kunkel L., Grillo-Lopez A.J., and Lo Buglio A.F. A pilot study of the anti-CD20 monoclonal antibody rituximab in patients with refractory immune thrombocytopenia Semin. Oncol. 27 2000 99 103
149. Samardzic T., Marinkovic D., Danzer C.-P., Gerlach J., Nitschke L., and Wirth T. Reduction of marginal zone B cells in CD22-deficient mice Eur. J. Immunol. 32 2002 561 567
150. Santiago M.L., Mary C., Parzy D., Jacquet C., Montagutelli X., Parkhouse R.M.E., Lemoine R., Izui S., and Reininger L. Linkage of a major quantitative trait locus to Yaa gene-induced lupus-like nephritis in (NZW x C57BL/6)F1 mice Eur. J. Immunol. 28 1998 4257 4267
151. Saouaf S.J., Mahajan S., Rowley R.B., Kut S.A., Fargnoli J., Burkhardt A.L., Tsukada S., Witte O.N., and Bolen J.B. Temporal differences in the activation of three classes of non-transmembrane protein tyrosine kinases following B-cell antigen receptor surface engagement Proc. Natl. Acad. Sci. USA 91 1994 9524 9528
152. Sato S., Hasegawa M., Fujimoto M., Tedder T.F., and Takehara K. Quantitative genetic variation in CD19 expression correlates with autoimmunity in mice and humans J. Immunol. 165 2000 6635 6643
153. Sato S., Jansen P.J., and Tedder T.F. CD19 and CD22 reciprocally regulate Vav tyrosine phosphorylation during B lymphocyte signaling Proc. Natl. Acad. Sci. USA 94 1997 13158 13162
154. Sato S., Miller A.S., Inaoki M., Bock C.B., Jansen P.J., Tang M.L.K., and Tedder T.F. CD22 is both a positive and negative regulator of B lymphocyte antigen receptor signal transduction: Altered signaling in CD22-deficient mice Immunity 5 1996 551 562
155. Sato S., Ono N., Steeber D.A., Pisetsky D.S., and Tedder T.F. CD19 regulates B lymphocyte signaling thresholds critical for the development of B-1 lineage cells and autoimmunity J. Immunol. 157 1996 4371 4378
156. Sato S., Steeber D.A., Jansen P.J., and Tedder T.F. CD19 expression levels regulate B lymphocyte development: Human CD19 restores normal function in mice lacking endogenous CD19 J. Immunol. 158 1997 4662 4669
157. Sato S., Tuscano J.M., Inaoki M., and Tedder T.F. CD22 negatively and positively regulates signal transduction through the B lymphocyte antigen receptor Semin. Immunol. 10 1998 287 297
158. Sausville E.A., Headlee D., Stetler-Stevenson M., Jaffe E.S., Solomon D., Figg W.D., Herdt J., Kopp W.C., Rager H., and Steinberg S.M. Continuous infusion of the anti-CD22 immunotoxin IgG-RFB4-SMPT-dgA in patients with B-cell lymphoma: A phase I study Blood 85 1995 3457 3465
159. ras oncoprotein activators SHC and mSOS1 as well as assembly of complexes containing SHC, GRB-2, mSOS1, and a 145-kDa tyrosine-phosphorylated protein J. Immunol. 153 1994
160. 3)/Tec kinase-dependent calcium signaling pathway: A target for SHIP-mediated inhibitory signals EMBO J. 17 1998 1961 1972
161. Scharenberg A.M., and Kinet J.-P. The emerging field of receptor-mediated inhibitory signaling: SHP or SHIP? Cell 87 1996 961 964
162. Schulte R.J., Campbell M.A., Fischer W.H., and Sefton B.M. Tyrosine phosphorylation of CD22 during B-cell activation Science 258 1992 1001 1004
163. Schultz L.D., Schweitzer P.A., Ranjan T.V., Yi T., Ihle J.N., Matthews R.J., Thomas M.L., and Beier D.R. Mutations at the murine motheaten locus are within the hematopoietic cell protein-tyrosine phosphatase (Hcph) gene Cell 73 1993 1445 1454
164. Schwarting R., Stein H., and Wang C.Y. The monoclonal antibodies αS-HCL 1 (αLeu-14) and αS-HCL 3 (αLeu-M5) allow the diagnosis of hairy cell leukemia Blood 65 1985 974 983
165. Schwartz-Albiez R., Dörken B., Monner D.A., and Moldenhauer G. CD22 antigen: Biosynthesis, glycosylation, and surface expression of a B lymphocyte protein involved in B-cell activation and adhesion Int. Immunol. 3 1991 623 633
166. Segundo C., Rodriguez C., Garcia-Poley A., Aguilar M., Gavilan I., Bellas C., and Brieva J.A. Thyroid-infiltrating B lymphocytes in Graves' disease are related to marginal zone and memory B-cell compartments Thyroid 11 2001 525 530
167. Sgroi D., Varki A., Braesch-Andersen S., and Stamenkovic I. CD22, a B-cell-specific immunoglobulin superfamily member, is a sialic acid-binding lectin J. Biol. Chem. 268 1993 7011 7018
168. Shan D., and Press O.W. Constitutive endocytosis and degradation of CD22 by human B cells J. Immunol. 154 1995 4466 4475
169. Shen G.-L., Li J.-A., Ghetie M.-A., Ghetie V., May R.D., Till M., Brown A.N., Relf M., Knowles P., Uhr J.W., Janossy G., Amlot P., Vitetta E.S., and Thorpe P.E. Evaluation of four CD22 antibodies as ricin A-chain-containing immunotoxins for the in vivo therapy of human B-cell leukemias and lymphomas Intl. J. Cancer 42 1988 792 797
170. Shih L.B., Lu H.H.Z., Xuan H., and Goldenberg D.M. Internalization and intracellular processing of an anti-B-cell lymphoma monoclonal antibody, LL2 Int. J. Cancer 56 1994 538 545
171. Kip1 by two mechanisms, ubiquitin-mediated degradation and proteolytic processing J. Biol. Chem. 274 1999 13886 13893
172. Shlomchik M.J., Madaio M.P., Ni D., Trounstine M., and Huszar D. The role of B cells in lpr/lpr-induced autoimmunity J. Exp. Med. 180 1994 1295 1306
173. Sidman C.L., Shultz L.D., and Unanue E.R. The mouse mutant "Motheaten." Functional studies of the immune system J. Immunol. 121 1978 2399 2404
174. Sieber T., Schoeler D., Ringel F., Pascu M., and Schreiver F. Selective internalization of monoclonal antibodies by B-cell chronic lymphocytic leukaemia cells Brit. J. Hematol. 121 2003 458 461
175. Siegel A.B., Goldenberg D.M., Cesano A., Coleman M., and Leonard J.P. CD22-directed monoclonal antibody therapy for lymphoma Semin. Oncol. 30 2003 457 464
176. Simmons D., and Seed B. Isolation of a cDNA encoding CD33, a differentiation antigen of myeloid progenitor cells J. Immunol. 141 1988 2797 2800
177. Somani A., Yuen K., Xu F., Zhang J., Branch D.R., and Siminovitch K.A. The SH2 domain containing tyrosine phosphatase-1 down-regulates activation of Lyn and Lyn-induced tyrosine phosphorylation of the CD19 receptor in B cells J. Biol. Chem. 276 2001 1938 1944
178. Stamenkovic I., and Seed B. The B-cell antigen CD22 mediates monocyte and erythrocyte adhesion Nature 344 1990 74 77
179. Stamenkovic I., Sgroi D., Aruffo A., Sy M.S., and Anderson T. The B lymphocyte adhesion molecule CD22 interacts with leukocyte common antigen CD45RO on T cells and α2,6 sialyltransferase, CD75, on B cells Cell 66 1991 1133 1144
180. Stasi R., Pagano A., Stipa E., and Amadori S. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura Blood 98 2001 952 957
181. Stasi R., Stipa E., Forte V., Meo P., and Amadori S. Variable patterns of response to Rituximab threatment in adults with chronic idiopathic thrombocytopenic purpura Blood 99 2002 3872 3873
182. Stein R., Belisle E., Hansen H.J., and Goldenberg D.M. Epitope specificity of the anti-(B-cell lymphoma) monoclonal antibody, LL2 Cancer Immunol. Immunother. 37 1993 293 298
183. Strasser A., Whittingham S., Vaux D.L., Bath M.L., Adams J.M., Cory S., and Harris A.W. Enforced BCL2 expression in B-lymphoid cells prolongs antibody responses and elicits autoimmune disease Proc. Natl. Acad. Sci. USA 88 1991 8661 8665
184. Symington F.W., Subbarao B., Mosier D.E., and Sprent J. Lyb-8.2: A new B-cell antigen defined and characterized with a monoclonal antibody Immunogenetics 16 1982 381 391
185. Takata M., and Kurosaki T. A role for Bruton's tyrosine kinase in B-cell antigen receptor-mediated activation of phospholipase C-γ2 J. Exp. Med. 184 1996 31 40
186. 2+ mobilization through distinct pathways EMBO J. 13 1994 1341 1349
187. Tarakhovsky A., Turner M., Shaal S., Mee P.J., Duddy L.P., Rajewsky K., and Tybulewicz V. Defective antigen receptor-mediated proliferation of B and T cells in the absence of Vav Nature 374 1995 467 470
188. Tedder T.F. Response-regulators of B lymphocyte signaling thresholds provide a context for antigen receptor signal transduction Semin. Immunol. 10 1998 259 265
189. Tedder T.F., Inaoki M., and Sato S. The CD19/21 complex regulates signal transduction thresholds governing humoral immunity and autoimmunity Immunity 6 1997 107 118
190. Tedder T.F., Poe J.C., Fujimoto M., Haas K.M., and Sato S. The CD19-CD21 signal transduction complex of B lymphocytes regulates the balance between health and autoimmune disease: Systemic sclerosis as a model system Curr. Dir. Autoimmunity 8 2005 55 90
191. Tedder T.F., Sato S., Poe J.C., and Fujimoto M. CD19 and CD22 regulate a B lymphocyte signal transduction pathway that contributes to autoimmunity Keio J. Med. 49 2000 1 13
192. Tedder T.F., Tuscano J., Sato S., and Kehrl J.H. CD22, a B lymphocyte-specific adhesion molecule that regulates antigen receptor signaling Ann. Rev. Immunol. 15 1997 481 504
193. Theofilopoulos A.N. R.G. Lahita "Systemic Lupus Erythematosus" 1992 Churchill Livingston Edinburgh 121 195
194. Thomas M.L., and Brown E.J. Positive and negative regulation of Src-family membrane kinases by CD45 Immunol. Today. 20 1999 406 411
195. Tooze R.M., Doody G.M., and Fearon D.T. Counterregulation by the coreceptors CD19 and CD22 of MAP kinase activation by membrane immunoglobulin Immunity 7 1997 59 67
196. Torres R.M., Law C.-L., Santos-Argumedo L., Kirkham P.A., Grabstein K., Parkhouse R.M.E., and Clark E.A. Identification and characterization of the murine homologue of CD22, a B lymphocyte-restricted adhesion molecule J. Immunol. 149 1992 2641 2649
197. Tsubata T., Wu J., and Honjo T. B-cell apoptosis induced by antigen receptor crosslinking is blocked by a T-cell signal through CD40 Nature 12 1993 645 648
198. Tsui H.W., Siminovitch K.A., de Souza L., and Tsui F.W.L. Motheaten and viable motheaten mice have mutations in the hemopoietic cell phosphatase gene Nat. Genet. 4 1993 124 129
199. Tuscano J., Engel P., Tedder T.F., and Kehrl J.H. Engagement of the adhesion receptor CD22 triggers a potent stimulatory signal for B cells and blocking CD22/CD22L interactions impairs T-cell proliferation Blood 87 1996 4723 4730
200. Tuscano J.M., Engel P., Tedder T.F., Agarwal A., and Kehrl J.H. Involvement of p72syk kinase, p53/56lyn kinase and phosphatidyl inositol-3 kinase in signal transduction via the human B lymphocyte antigen CD22 Eur. J. Immunol. 26 1996 1246 1252
201. Tuscano J.M., Harris G., and Tedder T.F. B lymphocytes contribute to autoimmune disease pathogenesis: Current trends and clinical implications Autoimmunity Rev. 2 2003 101 108
202. 90Y-DOTA-peptide-Lym-1 in lymphoma xenografts Blood 101 2003 3641 3647
203. Tuscano J.M., Riva A., Toscano S.N., Tedder T.F., and Kehrl J.H. CD22 cross-linking generates B-cell antigen receptor-independent signals that activate the JNK/SAPK signaling cascade Blood 94 1999 1382 1392
204. Uchida J., Hamaguchi Y., Oliver J.A., Ravetch J.V., Poe J.C., Haas K.M., and Tedder T.F. The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy J. Exp. Med. 199 2004 1659 1669
205. van der Merwe P.A., Crocker P.R., Vinson M., Barclay A.N., Schauer R., and Kelm S. Localization of the putative sialic acid-binding site on the immunoglobulin superfamily cell-surface molecule CD22 J. Biol. Chem. 271 1996 9273 9280
206. Van Horssen P.J., Preijers F.W.M.B., Van Oosterhout Y.V.J.M., and De Witte T. Highly potent CD22-recombinant ricin A results in complete cure of disseminated malignant B-cell xenografts in SCID mice but fails to cure solid xenografts in nude mice Intl. J. Cancer 68 1996 378 383
207. Vanhaesebroeck B., Leevers S.J., Ahmadi K., Timms J., Katso R., Driscoll P.C., Woscholski R., Parker P.J., and Waterfield M.D. Synthesis and function of 3-phosphorylated inositol lipids Ann. Rev. Biochem. 70 2001 535 602
208. Viemann D., Schlenke P., Hammers H.J., Kirchner H., and Kruse A. Differential expression of the B-cell-restricted molecule CD22 on neonatal B lymphocytes depending upon antigen stimulation Eur. J. Immunol. 30 2000 550 559
209. Vita S.D., Zaja F., Sacco S., Candia A.D., Fanin R., and Ferraccioli G. Efficacy of selective B-cell blockade in the treatment of rheumatoid arthritis: Evidence for a pathogenetic role of B cells Arthritis Rheum. 46 2002 2029 2033
210. Vitetta E.S., Stone M., Amlot P., Fay J., May R., Till M., Newman J., Clark P., Collins R., and Cunningham D. Phase I immunotoxin trial in patients with B-cell lymphoma Cancer Res. 51 1991 4052 4058
211. Wakabayashi C., Adachi T., Wienands J., and Tsubata T. A distinct signaling pathway used by the IgG-containing B-cell antigen receptor Science 298 2002 2392 2395
212. Wellmann U., Werner A., and Winkler T.H. Altered selection processes of B lymphocytes in autoimmune NZB/W mice, despite intact central tolerance against DNA Eur. J. Immunol. 31 2001 2800 2810
213. Weng W.K., Jarvis L., and LeBien T.W. Signaling through CD19 activates vav/mitogen-activated protein kinase pathway and induces formation of a CD19/vav/phosphatidylinositol 3-kinase complex in human B-cell precursors J. Biol. Chem. 269 1994 32514 32521
214. Wilson G.L., Fox C.H., Fauci A.S., and Kehrl J.H. cDNA cloning of the B-cell membrane protein CD22: A mediator of B-B-cell interactions J. Exp. Med. 173 1991 137 146
215. Wilson G.L., Najfeld V., Kozlow E., Menniger J., Ward D., and Kehrl J.H. Genomic structure and chromosomal mapping of the human CD22 gene J. Immunol. 150 1993 5013 5024
216. Wither J.E., Roy V., and Brennan L.A. Activated B cells express increased levels of costimulatory molecules in young autoimmune NZB and (NZB x NZW)F(1) mice Clin. Immunol. 94 2000 51 63
217. Yang J.Q., Singh A.K., Wilson M.T., Satoh M., Stanic A.K., Park J.J., Hong S., Gadola S.D., Mizutani A., Kakumanu S.R., Reeves W.H., Cerundolo V., Joyce S., Van Kaer L., and Singh R.R. Immunoregulatory role of CD1d in the hydrocarbon oil-induced model of lupus nephritis J. Immunol. 171 2003 2142 2153
218. Yohannan J., Wienands J., Coggeshall K.M., and Justement L.B. Analysis of tyrosine phosphorylation-dependent interactions between stimulatory effector proteins and the B-cell co-receptor CD22 J. Biol. Chem. 274 1999 18769 18776
219. Yu Z.K., Gervais J.L., and Zhang H. Human CUL-1 associates with the SKP1/SKP2 complex and regulates p21(CIP1/WAF1) and cyclin D proteins Proc. Natl. Acad. Sci. USA 95 1998 11324 11329
220. Zeng D., Lee M.K., Tung J., Brendolan A., and Strober S. Cutting edge: A role for CD1 in the pathogenesis of lupus in NZB/NZW mice J. Immunol. 164 2000 5000 5004
221. Zhang M., and Varki A. Cell surface sialic acids do not affect primary CD22 interactions with CD45 and surface IgM nor the rate of constitutive CD22 endocytosis Glycobiology 14 2004 939 949
222. Zhang R., Alt F.W., Davidson L., Orkin S.H., and Swat W. Defective signaling through the T- and B-cell antigen receptors in lymphoid cells lacking the Vav proto-oncogene Nature 374 1995 470 473
223. Skp2 SCF ubiquitin ligase complex Nature 416 2002 703 709